Scarica l'app Stockscreener
1.31
0.00%
0.00
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché LXRX Giù?
Forum
Previsione
Frazionamento azionario
Lexicon Pharmaceuticals Inc Borsa (LXRX) Ultime notizie
How rising interest rates impact Lexicon Pharmaceuticals Inc. stock2025 Analyst Calls & Free Daily Entry Point Trade Alerts - mfd.ru
Lexicon Pharmaceuticals (NASDAQ:LXRX) Stock Crosses Above 200 Day Moving AverageHere's Why - MarketBeat
Sentiment Recap: Does Lexicon Pharmaceuticals Inc meet Warren Buffetts criteriaTrade Risk Summary & Verified Momentum Stock Watchlist - baoquankhu1.vn
Lexicon Pharmaceuticals completes $100 million stock offering By Investing.com - Investing.com Nigeria
Lexicon Pharmaceuticals completes $100 million stock offering - Investing.com
Lexicon Announces Closing of Approximately $94.6 Million Public Offering and Concurrent Private Placement - The Manila Times
Lexicon Pharmaceuticals Completes Public Offering of Common Stock and Concurrent Private Placement - Quiver Quantitative
Lexicon raises about $94.6M to fund drug work and operations - Stock Titan
Lexicon Pharmaceuticals prices $94.6M share offering - MSN
Insider Buying: Lexicon Pharmaceuticals (NASDAQ:LXRX) Director Acquires 1,538,462 Shares of Stock - MarketBeat
Market Review: How does Lexicon Pharmaceuticals Inc compare to its peersWeekly Market Outlook & Safe Capital Growth Trade Ideas - baoquankhu1.vn
Lexicon Pharmaceuticals Bolsters Capital Through Equity Financing - The Globe and Mail
Lexicon Pharmaceuticals Signs Multiple Material Agreements - TradingView
FOMO Trade: Does Lexicon Pharmaceuticals Inc meet Warren Buffetts criteria2025 Momentum Check & Capital Protection Trade Alerts - baoquankhu1.vn
Lexicon Pharmaceuticals Initiates Stock Offering to Drive R&D Growth - StocksToTrade
Lexicon Pharmaceuticals Stock Offering: Strategic Move to Boost R&D - timothysykes.com
Pullback Watch: Can Lexicon Pharmaceuticals Inc reach all time highs this yearWeekly Trading Summary & Technical Pattern Alert System - baoquankhu1.vn
Lexicon Pharmaceuticals Announces Key Stock Offering amid Strategic Funding Efforts - StocksToTrade
Lexicon Pharmaceuticals prices public offering at $1.30 per share By Investing.com - Investing.com Nigeria
Lexicon Pharmaceuticals launches public offering of common stock By Investing.com - Investing.com Australia
Citi Raises Lexicon Pharmaceuticals (LXRX) Outlook on Strength of Novo Nordisk Partnership Milestones - Finviz
Lexicon Pharmaceuticals stock tumbles on public offering pricing By Investing.com - Investing.com Canada
Lexicon Pharmaceuticals (LXRX) Engages Jefferies and Piper Sandl - GuruFocus
Lexicon Pharmaceuticals stock tumbles on public offering pricing - Investing.com India
Lexicon Pharmaceuticals (LXRX) Raises $41.6M Through Public Offe - GuruFocus
Lexicon Pharmaceuticals prices public offering at $1.30 per share - Investing.com
Lexicon Announces Pricing of Approximately $94.6 Million Public Offering and Concurrent Private Placement - The Manila Times
Lexicon announces pricing of approximately $94.6 million public offering at $1.30 per share - marketscreener.com
Drug developer Lexicon raises $94.6M to fund pipeline and operations - stocktitan.net
Lexicon Pharmaceuticals (LXRX) Initiates Public Stock Offering - GuruFocus
Lexicon Pharmaceuticals (LXRX) Launches Public Offering, Shares Dip - GuruFocus
Lexicon Pharmaceuticals launches public offering of common stock - Investing.com
Lexicon Announces Proposed Public Offering of Common Stock - The Manila Times
Lexicon (NASDAQ: LXRX) plans stock sale, highlights late-stage pipeline - stocktitan.net
Lexicon plans stock sale to fund drug candidate research, operations - Stock Titan
Lexicon Pharmaceuticals (NASDAQ:LXRX) Shares Down 8.5%Should You Sell? - MarketBeat
Lexicon Pharmaceuticals Rings the Closing Bell - Nasdaq
How A Reset Price Target Is Reframing The Story For Lexicon Pharmaceuticals (LXRX) - Yahoo Finance
Risk Report: Can Lexicon Pharmaceuticals Inc reach all time highs this year - baoquankhu1.vn
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Given Consensus Rating of "Hold" by Brokerages - MarketBeat
Lexicon Pharma spikes after FDA feedback on pain drug - MSN
Lexicon Pharmaceuticals Inc (NASDAQ:LXRX) Shows High-Growth Momentum with Strong Technical and Fundamental Trends - ChartMill
1.12%
0.87%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):